Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). - Wikidata - awgldk - TriplyDB

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).

http://www.wikidata.org/entity/Q35213324

about

Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization : Analysis of a medical claims database.The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients Similarities and Distinctions in Actions of Surface-Directed and Classic Androgen Receptor Antagonists.Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1)Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials.Radium-223 international early access program: results from the Spanish subset.

P2860

Q33841309-95AB8C72-3B6C-456A-9C1E-E8DC7CE26D11 Q34525556-5F622541-1372-4750-AB22-CD64EFA22107 Q35655761-C1D887C9-57C2-468F-90B7-4814B384A7A0 Q35762232-07CF9AED-B5D6-4D76-A9C8-B09554EA773D Q36997189-7FA8C70C-6727-4461-B234-810D64AF9F09 Q41709181-84783FA3-8DCE-4CC8-A735-35112939D084 Q47786425-4A51E17C-3538-4AA7-AFC4-57719BBB59AD

P2860

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).

http://www.wikidata.org/entity/Q35213324

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Changing paradigms in manageme ...... stant Prostate Cancer (mCRPC).

@ast

Changing paradigms in manageme ...... stant Prostate Cancer (mCRPC).

@en

type

label

Changing paradigms in manageme ...... stant Prostate Cancer (mCRPC).

@ast

Changing paradigms in manageme ...... stant Prostate Cancer (mCRPC).

@en

prefLabel

Changing paradigms in manageme ...... stant Prostate Cancer (mCRPC).

@ast

Changing paradigms in manageme ...... stant Prostate Cancer (mCRPC).

@en

P1433

Q35213324-DBF06335-4CF4-4A20-8147-4A1C9E29D7BA

P1476

Q35213324-D6ABDF80-E307-48FF-BEF0-0FD449C30429

P2093

Q35213324-2CFCC30A-4DD1-4B1A-862A-C5C1C105D74E

Q35213324-6802ECA2-E2C8-4F79-B2D9-EA76F9547F4F

Q35213324-E1F954D1-477D-431A-A387-D6A890D761B6

P275

Q35213324-A1C3E80F-0AF9-4650-9ACE-1872C49C8E53

P2860

Q35213324-058E8E8F-2FA1-4451-8FB4-94D6A5240611

Q35213324-082A02D0-C83C-4FC2-A224-07AF450263C0

Q35213324-0EF0513E-70CC-452D-9CA4-11B54C1DBADC

Q35213324-11AA840A-72BE-4832-80D5-2E67CA26B6F6

Q35213324-13493F2C-BBFE-42D9-9254-1AB19FCC1ACE

Q35213324-156554DF-8602-46C6-8119-94C30DA786CA

Q35213324-17451EE4-7125-4EE1-91CD-1AA1C695FDDF

Q35213324-2BBD9690-AFE0-42F2-ACB7-954A7FB82C76

Q35213324-3C8DD589-F543-4780-B063-0B1F37340AD0

Q35213324-4BD72D80-06A2-4E0E-890C-5764C6D3F375

P2888

Q35213324-80C6CDE2-F1B2-4343-89A5-06BB2C3ED955

P304

Q35213324-EE7FE337-0B8A-43FE-B440-B19E10228026

P31

Q35213324-3E146E8B-EC7B-4B5F-BC26-E03F6D617175

Q35213324-5855E57D-C179-43A9-9CD8-3B21A38C40ED

P356

Q35213324-F7D586F8-52BC-41FF-9B3A-3F80388CD73D

P478

Q35213324-E5A3D9C7-2EA3-4216-9BFA-BF84C496252B

P5008

Q35213324-93848E64-4A55-416A-A613-739A7B3FA5C3

P577

Q35213324-112B3B1F-820D-4764-A543-298B4D434239

P5875

Q35213324-C66BD5D1-AC69-4611-A8E3-D16CE5049D57

P6179

Q35213324-770D0DEB-2C35-45D6-805C-2BB773632191

P698

Q35213324-B52838B5-6CF2-4471-AA48-F1E5336589A8

P921

Q35213324-08D68A08-0844-47B3-9675-37189130F992

P932

Q35213324-F18854F9-B32E-474F-AB9D-5CDEAF1F28AF

P356

1471-2490-14-55

P1433

P1476

Changing paradigms in manageme ...... stant Prostate Cancer (mCRPC).

@en

P2093

Eva Gupta

http://www.w3.org/2001/XMLSchema#string

Troy Guthrie

http://www.w3.org/2001/XMLSchema#string

Winston Tan

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Abiraterone in metastatic prostate cancer without previous chemotherapy

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Cancer statistics, 2013

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

Complete androgen blockade for prostate cancer: what went wrong?

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

P2888

1471-2490-14-55

P304

55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2490-14-55

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2014-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264246209

http://www.w3.org/2001/XMLSchema#string

P6179

1018854679

http://www.w3.org/2001/XMLSchema#string

P698

25062956

http://www.w3.org/2001/XMLSchema#string

P921

castration-resistant prostatic neoplasm

P932

4167156

http://www.w3.org/2001/XMLSchema#string